FTC Requires Aurobindo to Divest Four Generic Drugs to Protect Competition in $250 Million Lannett Acquisition
核心洞察
The FTC approved Aurobindo's $250 million acquisition of Lannett on the condition that four generic drug products be divested to Quagen Pharmaceuticals (搜索) LLC to preserve market competition.
The divested products include mycophenolate mofetil oral suspension, niacin ER tablets, pilocarpine tablets, and rabeprazole sodium DR tablets, which treat conditions from organ transplant rejection to dry mouth.
Without the divestitures, the FTC alleged the deal would eliminate competition between two of a limited number of competitors, potentially raising generic drug prices for millions of patients.
The Federal Trade Commission has required Aurobindo Pharma Limited to divest four generic drug products as a condition of completing its $250 million acquisition of Lannett Company (搜索) Inc., a move the agency says will protect American patients from higher drug costs. The proposed consent order, approved by a 2-0 Commission vote, mandates that the divested products be transferred to Quagen Pharmaceuticals (搜索) LLC, an experienced generic pharmaceutical company.
The acquisition, announced by Aurobindo Pharma USA, Inc., combines two competitors in markets for four generic pharmaceuticals that provide critical relief for patients. Lannett, a Pennsylvania-based generic pharmaceutical company, specializes in complex, non-opioid controlled substances and operates a manufacturing facility in Seymour, Indiana with capacity to scale production to approximately 4 billion doses annually.
"The FTC has shown a deep commitment to lowering drug prices for all Americans," said Daniel Guarnera, Director of the FTC's Bureau of Competition. "The FTC's action today will protect millions of patients from the threat of higher generic drug prices, allowing Americans to focus on their health and not on how much a specific drug is going to cost."
Four Products Subject to Divestiture
Under the terms of the consent order, Aurobindo must divest the following four generic pharmaceutical products to Quagen Pharmaceuticals (搜索) LLC:
- Mycophenolate mofetil oral suspension — an immunosuppressant prescribed to help prevent organ transplant rejection.
- Niacin extended release (ER) tablets — a drug used to manage cholesterol levels and to prevent or manage niacin, a B-complex vitamin, deficiency.
- Pilocarpine tablets — a drug used to treat dry mouth, often after radiation therapy for head and neck cancer or in patients with Sjögren's syndrome, an autoimmune disease causing the immune system to attack moisture-producing glands.
- Rabeprazole sodium delayed release (DR) tablets — a proton pump inhibitor used to reduce stomach acid, indicated for the treatment of duodenal ulcers, gastroesophageal reflux disease, and Zollinger-Ellison syndrome.
Competition Concerns Addressed
The FTC's complaint alleged that without the divestitures, Aurobindo's acquisition of Lannett would eliminate competition between the two drug manufacturers, reducing the number of independent significant competitors for each of the four generic drugs. The deal would increase the likelihood that Aurobindo could unilaterally exercise market power in these drug markets, while remaining competitors could engage in coordinated interaction, potentially raising the cost of generic drugs.
The consent order also specifies that Aurobindo and Lannett must provide transition services to enable Quagen to effectively operate the divested assets immediately. Both companies will be subject to a monitor to oversee compliance obligations.
Strategic Rationale and Financial Impact
Aurobindo Pharma USA CEO Swami S. Iyer characterized the acquisition as "a highly compelling strategic and financial opportunity," noting it accelerates revenue growth, strengthens U.S.-based manufacturing capabilities, and enhances the company's position in complex, non-opioid controlled substances.
Lannett CEO Tim Crew expressed optimism about the combined entity: "Aurobindo's market reach and resources will help make our portfolio of medicines even more affordable and accessible for patients everywhere."
The transaction, valued at $250 million on a cash-free, debt-free basis and inclusive of normalized working capital, is expected to close before the end of June 2026. Aurobindo stated the acquisition is expected to be immediately accretive to the group's earnings per share and anticipates meaningful cost efficiencies, SG&A synergies, and operational integration advantages.
The public will have 30 days to submit comments on the proposed consent agreement package through Regulations.gov.